SOURCE: Interpretive Guidance Document for Sustainable Futures Summary Assessment Human Health Hazard - Cancer Updated June 2006

Interpretation of OncoLogic Results:

SF Concern	OncoLogic Results	Definition - OncoLogic Result
Low	Low	Unlikely to be a carcinogen
Further Research Needed	Marginal	Likely to have equivocal carcinogenic activity
Moderate	Low-Moderate	Likely to be weakly carcinogenic
	Moderate	Likely to be moderately active carcinogen
High	Moderate-High	Highly likely to be a moderately active carcinogen
	High	Highly likely to be a potent carcinogen

Interpretation of Experimental Data:

SF Concern	Definition - Experimental Data	
Low	Negative experimental data	
Moderate	Positive cancer bioassay in experimental animals or chemical class known to produce carcinogenic effects	
High	Positive experimental data in humans (e.g. epidemiology study)	

NOTE: Measured data from a properly conducted study on the SF chemical or a relevant analog always takes precedence over predicted data.

Human Health Hazard - Non-Cancer

Criteria for Assigning Non-Cancer Hazard Concern Levels:

SF Concern	Definition - Experimental Data	
Low	No basis for concern identified or systemic toxicity with NOAEL \ge 1000 mg/kg/day; only minor clinical signs of toxicity; liver and/or kidney weight increase or clinical chemistry changes with LOAEL \ge 500 mg/kg/day	
Moderate	Suggestive animal studies for chemical or analog(s) <i>or</i> chemical class known to produce toxicity <i>or</i> organ pathology (gross and/or microscopic) with LOAEL < 500 mg/kg/day; clinical chemistry changes and organ weight changes at < 500 mg/kg/day; NOAEL < 1000 mg/kg/day	
High	Evidence of adverse effects in humans <i>or</i> conclusive evidence of severe effects in animal studies. Death organ pathology (microscopic) at LOAEL ≤ 100 mg/kg/day; multiple organ toxicity; NOAEL ≤ 10 mg/kg/day.	

NOTE: Most often, regulatory decisions will be made based on the following human health effects: reproductive; immune; developmental; neurotoxicity; and systemic. If analog data are used, absorption considerations should be made for the chemical of interest.

NOTE: Guidance on the evaluation of non-cancer human health concerns of polymers can be found in: P2 Framework Manual, Oct 2003 version, edited Jan 2004, pg. 169-170 at http://www.epa.gov/oppt/p2framework/docs/p2manua.htm